A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects

Cardiovascular Disease Clinical Trial

Official title:

A Fixed Sequence, Open-Label Study to Assess the Effect of Multiple Doses of AZD5718 on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04492709
• Other study ID #: D7550C00011
• Status: Completed
• Phase: Phase 1
• Start date: July 30, 2020
• Est. completion date: October 19, 2020

Study information

• Verified date: October 2020
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In clinical practice, AZD5718 will be co-administered with CYP3A substrates. Therefore, it is important to determine the impact of AZD5718 on the pharmacokinetics (PK) of CYP3A4 substrates. The primary objective of this study is to evaluate the effect of AZD5718 on the PK of midazolam, a known sensitive CYP3A4 substrate.

Description:

This is a Phase 1, fixed sequence, open-label study in healthy subjects, performed at a single study center. This study will consist of 3 treatment periods to assess the PK of midazolam when administered alone and in combination with multiple doses of AZD5718. The study will comprise: - A screening period of maximum 28 days; - Three treatment periods during which subjects will be resident from the day before first dosing (Day -1) until at least 24 hours after last dosing (Day 7); discharged on the morning of Day 8, and; - A final Follow-up Visit within 5 to 7 days after the last administration of investigational medicinal product (IMP).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: October 19, 2020
• Est. primary completion date: October 19, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study specific procedures.
• Healthy male and female subjects aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
• Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at

screening by fulfilling one of the following criteria:

1. Postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone levels in the postmenopausal range.

2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.

• Male subject must adhere to the contraception methods details.
• Have a body mass index between 18.5 and 30 kg/m2, inclusive, and weigh at least 50 kg and no more than 100 kg, inclusive.

Exclusion Criteria:

• History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
• History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• History or presence of acute pulmonary insufficiency, marked neuromuscular respiratory weakness, obsessional states, phobic states, sleep apnea syndrome, or unstable myasthenia gravis.
• Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
• Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, at screening and/or on admission to the Clinical Unit, as judged

by the Investigator, including:

1. Alanine aminotransferase > 1.5 x upper limit of normal (ULN);

2. Aspartate aminotransferase > 1.5 x ULN;

3. Bilirubin (total) > 1.5 x ULN; and

4. Gamma glutamyl transpeptidase > 1.5 x ULN.

• Any clinically significant abnormal findings in vital signs (blood pressure and pulse; supine) at screening and/or admission to the Clinical Unit, as judged by the Investigator.
• Any clinically significant abnormalities on 12-lead electrocardiogram at screening, as judged by the Investigator.
• Any positive result on screening for serum hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus antibody.
• Known or suspected Gilbert syndrome.
• Known or suspected history of drug abuse in the last 2 years, as judged by the Investigator.
• Has received another new chemical or biological entity within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.
• Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
• History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator. History of hypersensitivity to drugs with a similar chemical structure or class to AZD5718 or known hypersensitivity to benzodiazepines or to any formulation excipients.
• Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.
• Positive screen for drugs of abuse or cotinine at screening or on admission to the study unit, or positive screen for alcohol on screening or on admission to the study unit.
• Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
• Use of any prescribed (other than hormone-replacement therapy for females) or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life.
• Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate) as judged by the Investigator. Excessive intake of caffeine defined as the regular consumption of more than 600 mg of caffeine per day or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the investigational site.
• Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the Investigator. Excessive intake of alcohol defined as the regular consumption of more than 24 g of alcohol per day for men or 12 g of alcohol per day for women.
• Involvement of any AstraZeneca, Parexel, or study site employee or their close relatives.
• Subjects who have previously received AZD5718.
• Subjects with history of lactose intolerance.
• Judgment by the Investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
• Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
• Subjects who cannot communicate reliably with the Investigator.

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases

Intervention

Drug:
• Midazolam
The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
• AZD5718
The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.

Locations

Country	Name	City	State
United Kingdom	Research Site	Harrow

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	Parexel

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum observed plasma peak concentration (Cmax) of midazolam	Comparison of Cmax calculated when midazolam alone and calculated when midazolam was taken together with AZD5718	Day 1-Day 2 and Day 7-Day 8: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours (h) post-dose
Primary	Area under plasma concentration-time curve from time zero to infinity (AUCinf) of midazolam	Comparison of AUCinf calculated when midazolam alone and calculated when midazolam was taken together with AZD5718	Day 1-Day 2 and Day 7-Day 8: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 h post-dose
Primary	Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast) of midazolam	Comparison of AUClast calculated when midazolam alone and calculated when midazolam was taken together with AZD5718	Day 1-Day 2 and Day 7-Day 8: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 h post-dose
Primary	Time to reach maximum observed plasma concentration (tmax) of midazolam	Comparison of tmax calculated when midazolam alone and calculated when midazolam was taken together with AZD5718	Day 1-Day 2 and Day 7-Day 8: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 h post-dose
Primary	Half-life (t1/2) of midazolam	Comparison of t1/2 calculated when midazolam alone and calculated when midazolam was taken together with AZD5718	Day 1-Day 2 and Day 7-Day 8: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 h post-dose
Primary	Plasma concentrations of AZD5718	AZD5718 Plasma concentrations will be evaluated at trough and also at the expected time of tmax	Day 2-Day 7: at trough and Day 7: 4 h post-dose
Secondary	Number of subjects with adverse events (AEs) and serious AEs	The number and percentage of subjects with AEs and the number of events including for both AZD5718 alone and in combination with midazolam	AE: From Day 1 to post-treatment follow-up visit (Day 13); SAE: From screening to post-treatment follow-up visit (Day 13)
Secondary	Number of subjects with abnormal 12-lead electrocardiogram (ECG)	12-lead resting ECG safety assessments if there are any abnormal findings or if the Investigator considers it is required for any other safety reason including for both AZD5718 alone and in combination with midazolam	At screening and post-treatment follow-up visit (Day 13)
Secondary	Number of subjects with abnormal physical examination	Any new or aggravated clinically relevant abnormal medical physical examination finding compared to the baseline assessment including for both AZD5718 alone and in combination with midazolam	At screening, Day -1, Day 1, Day 4, Day 7, Day 8, and post-treatment follow-up visit (Day 13)
Secondary	Number of subjects with abnormal blood pressure (BP)	Observed values and change from baseline value in systolic and diastolic BP including for both AZD5718 alone and in combination with midazolam	For approximately 6 weeks (from screening to post-treatment follow-up)
Secondary	Number of subjects with abnormal pulse rate	Observed values and change from baseline value in pulse rate including for both AZD5718 alone and in combination with midazolam	For approximately 6 weeks (from screening to post-treatment follow-up)
Secondary	Number of subjects with abnormal oxygen saturation levels	Observed values and change from baseline value in oxygen saturation including for both AZD5718 alone and in combination with midazolam	On Day 1 and Day 7: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8 and 12 h post-dose
Secondary	Number of subjects with abnormal hematology parameters	Observed values and change from baseline value in hematology including for both AZD5718 alone and in combination with midazolam	At screening, Day -1, Day 1 (pre-dose), Day 2 and Day 4 (pre-dose), Day 7 (pre-dose), Day 8, and post-treatment follow-up visit (Day 13)
Secondary	Number of subjects with abnormal clinical chemistry parameters	Observed values and change from baseline value in clinical chemistry including for both AZD5718 alone and in combination with midazolam	At screening, Day -1, Day 1 (pre-dose), Day 2 and Day 4 (pre-dose), Day 7 (pre-dose), Day 8, and post-treatment follow-up visit (Day 13)
Secondary	Number of subjects with abnormal urine analysis parameters	Observed values and change from baseline value in urine analysis including for both AZD5718 alone and in combination with midazolam	At screening, Day -1, Day 1 (pre-dose), Day 2 and Day 4 (pre-dose), Day 7 (pre-dose), Day 8, and post-treatment follow-up visit (Day 13)